OR WAIT null SECS
Novasep (Lyon, France) has announced a €6.1 million investment in its Mourenx site, Pyrénées-Atlantiques, France, to modernize its API manufacturing facility.
The modernization of the cGMP workshop includes the installation of new equipment and the revamping of clean rooms for API isolation, enhancing Novasep’s flexibility and developing capacity for the custom manufacturing of innovative therapeutic molecules. Additionally, Novasep has also announced the creation of seven full-time jobs on this site.
This project has been selected as part of the France Relance recovery plan initiated by the French government. Novasep will be supported within the framework of the “Investissements d’Avenir” (Investments for the future) programme, which rewards innovative and promising industrial investments.
“This investment sends a strong signal to our customers and partners by increasing our market competitiveness. It further supports our strategy of reinforcing our high-quality offer for the commercial production of innovative therapies,” said Michel Spagnol, Chairman and CEO of Novasep.
For more information please visit: www.novasep.com